Implementation and outcome of thrombolysis with alteplase 3-4·5 h after an acute stroke: an updated analysis from SITS-ISTR

The Lancet Neurology

Volumn 9, Issue 9, 2010, Pages 866-874

  Ahmed, Niaz ^a   Wahlgren, Nils ^a   Grond, Martin ^b   Hennerici, Michael ^c   Lees, Kennedy R ^d   Mikulik, Robert ^e   Parsons, Mark ^f   Roine, Risto O ^g   Toni, Danilo ^h   Ringleb, Peter ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Kreiskrankenhaus Siegen   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^f JOHN HUNTER HOSPITAL   (Australia)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK; STROKE; SYMPTOM; TREATMENT OUTCOME;

EID: 77955665657     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70165-4     Document Type: Article

References (18)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA 1995, 274:1017-1025.
3. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998, 352:1245-1251.
4. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999, 282:2019-2026.
5. Clark WM, Albers GW, Madden KP, Hamilton S The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000, 31:811-816.
6. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329. for the ECASS Investigators.
7. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Lancet Neurol 2008, 7:299-309. for the EPITHET investigators.
8. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363:768-774.
9. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703. for the ECASS, ATLANTISATLANTIS, NINDSNINDS, EPITHET rt-PA Study Group InvestigatorsEPITHET rt-PA Study Group Investigators.
10. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003, 3. CD000213.
11. Hill MD, Buchan AM Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005, 172:1307-1312. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators.
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369:275-282.
13. Wahlgren N, Ahmed A, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials; Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST). Stroke 2008, 39:3316-3322. for the SITS-MOST investigators.
14. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008, 372:1303-1309.
15. Should the time window for intravenous thrombolysis be extended? Karolinska Stroke Update Consensus Statement, (accessed April 5, 2010). http://www.strokeupdate.org/Cons_thrombolysis_2008.aspx.
16. Update Guidelines European Stroke Organisation, (accessed April 5, 2010). http://www.eso-stroke.org/pdf/ESO_Extended_Thrombolysis_KSU.pdf.
17. Del Zoppo GJ, Saver J, Jauch EC, Adams HP Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40:2945-2948. on behalf of the American Heart Association Stroke Council.
18. Lyden P, Raman R, Liu L, et al. National Institutes of Health Stroke Scale certification is reliable across multiple venues. Stroke 2009, 40:2507-2511.